[State of the kallikrein-kinin system in chronic circulatory insufficiency]

Kardiologiia
|March 1, 1979
PubMed

Insights

Chronic circulatory insufficiency activates the kinin system, indicated by reduced plasma prekallikrein. Cardiac glycoside treatment normalized kinin system indices alongside clinical improvement.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • The kallikrein-kinin system plays a role in cardiovascular function.
  • Chronic circulatory insufficiency is a complex condition affecting hemodynamics.
  • Understanding the kallikrein-kinin system's involvement may reveal therapeutic targets.

Purpose of the Study:

  • To investigate the kallikrein-kinin system's status in patients with chronic circulatory insufficiency.
  • To evaluate the impact of cardiac glycosides on the kallikrein-kinin system in these patients.

Main Methods:

  • Studied 93 patients with chronic circulatory insufficiency.
  • Assessed plasma prekallikrein and kallikrein inhibitor levels.
  • Analyzed changes in 25 patients before and after cardiac glycoside treatment, monitoring central hemodynamics.

Main Results:

  • All patients exhibited significant activation of the kinin system, evidenced by decreased plasma prekallikrein and altered kallikrein inhibitor levels.
  • Clinical improvement and enhanced central hemodynamics correlated with normalization of kinin system indices.
  • Patients intolerant to cardiac glycosides did not show restoration of kinin system components.

Conclusions:

  • The kallikrein-kinin system is activated in chronic circulatory insufficiency.
  • Cardiac glycoside therapy can normalize kinin system function in conjunction with clinical improvement.
  • Kinin system normalization may be a marker of successful cardiac glycoside treatment.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...